title: Antiplatelet therapy for patients with diabetes mellitus and acute coronary syndrome.
abstract: In diabetes mellitus, platelet hyperreactivity is common and may contribute to the high incidence of cardiovascular disease; dual antiplatelet therapy reduces the risk of recurrence. Prasugrel or ticagrelor provides a greater, more consistent antiplatelet effect than clopidogrel. Prasugrel provides greater clinical benefit than clopidogrel in patients with diabetes (hazard ratio [HR], 0.70; P<0.001) versus those without diabetes (HR, 0.86; P=0.02), due to greater reductions in cardiovascular events and no increased major bleeding. Similar clinical benefits are seen with ticagrelor versus clopidogrel in patients with and without diabetes. Evidence suggests that prasugrel/aspirin may provide particular advantages for patients with diabetes mellitus.
authors.affiliation: University of Oklahoma Health Sciences Center, Oklahoma City, OK, USA. jorge-saucedo@ouhsc.edu
authors.forename: Jorge Felix
authors.initials: JF
authors.lastname: Saucedo
mesh_terms: D054058:Acute Coronary Syndrome / Q000097:blood / Q000188:drug therapy* / Q000453:epidemiology; D001777:Blood Coagulation / Q000187:drug effects*; D003920:Diabetes Mellitus / Q000097:blood* / Q000453:epidemiology; D006470:Hemorrhage / Q000139:chemically induced; D006801:Humans; D018579:Patient Selection; D010975:Platelet Aggregation Inhibitors / Q000009:adverse effects / Q000627:therapeutic use*; D018570:Risk Assessment; D012307:Risk Factors; D016896:Treatment Outcome
chemical_list: D010975:Platelet Aggregation Inhibitors